Windtree Therapeutics (NASDAQ: WINT) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Windtree Therapeutics to similar businesses based on the strength of its analyst recommendations, institutional ownership, dividends, profitability, earnings, valuation and risk.

Earnings & Valuation

This table compares Windtree Therapeutics and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Windtree Therapeutics $3.23 million -$28.34 million -0.04
Windtree Therapeutics Competitors $224.58 million $58.11 million -0.98

Windtree Therapeutics’ peers have higher revenue and earnings than Windtree Therapeutics. Windtree Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Windtree Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -588.67% N/A -308.95%
Windtree Therapeutics Competitors -912.91% -186.15% -28.31%

Institutional & Insider Ownership

36.8% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 1.3% of Windtree Therapeutics shares are owned by insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Windtree Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Windtree Therapeutics’ peers have a beta of 1.12, suggesting that their average share price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Windtree Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 1 0 2.50
Windtree Therapeutics Competitors 166 554 1215 16 2.55

Windtree Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 3,900.00%. As a group, “Biotechnology” companies have a potential upside of 54.92%. Given Windtree Therapeutics’ higher possible upside, equities research analysts plainly believe Windtree Therapeutics is more favorable than its peers.

Summary

Windtree Therapeutics peers beat Windtree Therapeutics on 7 of the 12 factors compared.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.